- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03337243
Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis
May 5, 2020 updated by: Gary Hieronimus, Sport and Spine Rehab Clinical Research Foundation
The purpose of this study is to compare the pain, functioning and pain medication consumption of knee osteoarthritis (OA) patients who have allogenic cytokines derived from human amniotic membranes (HAM) and allogenic mesenchymal stem cells derived from human umbilical cord Wharton's Jelly (HUMCWJ) implanted into the affected knee with knee OA patients who self-select to be in a non-intervention control group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 60 patients will be recruited from Scott Medical Health Center in Pittsburgh, PA.
Inclusion criteria for the study are knee OA patients who are eligible for HAM and HUMCWJ therapy of their knee, no previous HAM or HUMCWJ therapy, between the ages of 50-85, independently residing in the community, no previously diagnosed cognitive decline or mental illness, and not taking pain medication more than once per week for a condition other than knee OA.
Recruitment will be done in two parts as participants will self-select to participate in one of two study groups.
All participants who elect to have the procedure done at the initial consultation, meet inclusion criteria, and agree to be in the study will be placed in Group 1. Participants who do not wish to have the procedure, meet inclusion and exclusion criteria, and agree to be in the study will be placed in Group 2. Those participants who are unsure about the procedure and need more time to decide will be contacted 2 weeks later and then group will be determined by their decision.
All participants will be required to sign a written informed consent prior to data collection.
Following written consent, all participants will undergo data collection (T0).
At T0, participants will complete a demographic and medication use questionnaire, the Western Ontario and McMaster Universities Arthritis Index (WOMAC), knee survey, and be timed during a single trial of three functional tasks.
Participants will also provide a pain rating while completing each of the functional tasks.
Group 1 will then undergo HAMS injection to the OA affected knee immediately following the testing battery.
Group 2 will delay the HAMS injection to the OA affected knee for at least 3 months or never receive the injection.
All participants will complete T1 data collection approximately 4 weeks following completion of T0 data collection and T2 data collection approximately 3 months following completion of T0 data collection.
The T1 and T2 data collections will use the same data collection procedures and questionnaires.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15220
- Scott Medical Health Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- knee OA patients who are eligible for HAM and HUMCWJ therapy of their knee, no previous HAM or HUMCWJ therapy, between the ages of 50-85, independently residing in the community, no previously diagnosed cognitive decline or mental illness, and not taking pain medication more than once per week for a condition other than knee OA
Exclusion Criteria:
- Allergy to or use of penicillin, streptomycin, emphotericin B or dimethylsulfoxide. DMSO allergies and any immunocompromised conditions will also be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAM and HUMCWJ Injections (Group 1)
Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
|
SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle.
The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays.
The Physician will insert the needle fully into the joint space and begin to expel the fluid.
He will achieve a continuous injection flow as he withdraws the needle back out of joint space.
Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered.
This will be done using the exact same protocol as the SURGENEX SurForce® injection.
|
No Intervention: Control (Group 2)
Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all.
Participants will be asked to keep track of pain management and therapy throughout the 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months
Time Frame: Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Baseline (T0), 4 weeks (T1), 3 months (T2)
|
|
Change in pain during sit-to-stand over 3 months
Time Frame: Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Participants will perform as many sit-to-stand movements as they can in 30 seconds and then will rate pain
|
Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Change in pain during supine to upright over 3 months
Time Frame: Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Participants will perform a supine to upright movement as quickly as they can and then will rate pain
|
Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Change in pain during ascent/decent stairs over 3 months
Time Frame: Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Participants will ascend and decent 10 stairs as quickly as they can and then will rate pain
|
Baseline (T0), 4 weeks (T1), 3 months (T2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2017
Primary Completion (Actual)
April 26, 2019
Study Completion (Actual)
April 26, 2019
Study Registration Dates
First Submitted
May 25, 2017
First Submitted That Met QC Criteria
November 6, 2017
First Posted (Actual)
November 8, 2017
Study Record Updates
Last Update Posted (Actual)
May 6, 2020
Last Update Submitted That Met QC Criteria
May 5, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- StemCell
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis
-
Northumbria Healthcare NHS Foundation TrustUniversity of YorkRecruitingKnee Arthritis | Hip ArthritisUnited Kingdom
-
MedShape, IncOrthopedic Foot and Ankle Center, Ohio; CurveBeam LLCRecruitingAnkle Arthritis | Arthritis FootUnited States
-
MedShape, IncUniversity of Alabama at BirminghamRecruitingAnkle Arthritis | Foot ArthritisUnited States
-
University of Alabama at BirminghamMedShape, IncRecruiting
-
MedShape, IncThe University of Texas Medical Branch, GalvestonRecruitingAnkle Arthritis | Foot ArthritisUnited States
-
Chang Gung Memorial HospitalNot yet recruitingArthritis Knee | Arthritis HipTaiwan
-
MedShape, IncSaint Alphonsus Medical GroupUnknownAnkle Arthritis | Foot ArthritisUnited States
-
Saint Alphonsus Regional Medical CenterCompletedArthritis Knee | Arthritis of HipUnited States
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; University of TorontoCompleted
-
Smith & Nephew, Inc.TerminatedRheumatoid Arthritis | Traumatic Arthritis | Osteo Arthritis ShouldersUnited States
Clinical Trials on HAM and HUMCWJ Injections
-
NewLink Genetics CorporationCompleted
-
Universitätsklinikum Hamburg-EppendorfTerminated
-
Institut National de la Recherche AgronomiqueCentre de Recherche en Nutrition Humaine d'AuvergneCompleted
-
Institut National de Recherche pour l'Agriculture...Centre de Recherche en Nutrition Humaine d'AuvergneCompletedColorectal CancerFrance
-
Philippine Dermatological SocietyCompletedTinea Imbricata
-
Vivozon, Inc.CompletedPost-Operative PainUnited States
-
Vivozon, Inc.CompletedPost-Operative PainUnited States
-
Centre Hospitalier Universitaire de BesanconRecruitingOsteonecrosis Due to Drugs, JawFrance
-
University of HelsinkiFazer GroupUnknownBlood Glucose Concentration
-
Actavis Inc.Completed